October 23, 2020
Video
New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.
Article
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.
Reports of hospitalized older adults with COVID-19 who do not experience the classic symptoms are on the rise.
October 22, 2020
A prospective study looked at the association of contract nursing and SARS-CoV-2 outbreaks.
The full approval is based on 3 randomized controlled trials showing benefit of remdesivir compared with placebo across multiple outcome assessments.
How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?
October 21, 2020
New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.
Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.
In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.
